Form 4: Oncotelic Therapeutics CEO Acquires Shares in Open Market Transaction

Oncotelic Therapeutics CEO, Trieu Vuong, purchased 298,499 shares of common stock at $0.0289 per share on November 22, 2024.

Summary

• On November 22, 2024, Trieu Vuong, the CEO and Chairman of Oncotelic Therapeutics, Inc., acquired 298,499 shares of the company's common stock.
• The shares were purchased on the open market at a price of $0.0289 per share.
• Following the transaction, Mr. Vuong directly owns 92,842,716 shares of Oncotelic common stock.
• He also indirectly owns 16,780,384 shares through Autotelic, Inc. and 6,872,529 shares through his spouse.

Sentiment

Score: 7

Explanation: The document reflects a positive sentiment due to the CEO's purchase of shares, indicating confidence in the company. However, it's a routine transaction, so the sentiment is not extremely high.

Positives

• The CEO's purchase of shares could be seen as a positive signal of confidence in the company's future prospects.

Industry Context

This type of transaction is common for company executives and is often closely watched by investors as it can signal management's confidence in the company's future.

Comparison to Industry Standards

• Insider trading activity is a common occurrence in publicly traded companies, and this transaction is within the normal range of such activities.
• It is common for CEOs to purchase shares in their own companies, and the size of this purchase is not unusual for a company of Oncotelic's size.

Stakeholder Impact

• The CEO's purchase of shares may positively influence investor confidence.

Key Dates

Keywords

Oncotelic Therapeutics, Trieu Vuong, stock purchase, insider trading, common stock, open market, share ownership